Peter MacCallum Cancer Centre

Research facility


Location: Melbourne, Australia (AU) AU

ISNI: 0000000403978434

ROR: https://ror.org/02a8bt934

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2023) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, et al. Journal article Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer (2023) Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, et al. Journal article Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery (2023) Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DD, Fasching P, et al. Journal article Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis (2022) Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, et al. Journal article GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study (2022) Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, et al. Journal article Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci (2022) Devries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, et al. Journal article MYB orchestrates T cell exhaustion and response to checkpoint inhibition (2022) Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knoepper K, Utzschneider DT, et al. Journal article Incorporating progesterone receptor expression into the PREDICT breast prognostic model (2022) Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, et al. Journal article Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes (2022) Mavaddat N, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R, Bolla MK, et al. Journal article